Cover Image
Market Research Report
Product code 
1085738

Herceptin Biosimilar Market, by Indication, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published: | Coherent Market Insights | 175 Pages | Delivery time: 2-3 business days

Price

Back to Top
Herceptin Biosimilar Market, by Indication, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Published: May 26, 2022
Coherent Market Insights
Content info: 175 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used for the treatment of breast cancer and gastric cancer. Herceptin is mainly used to treat patients suffering from cancer and diagnosed with HER2 receptor positive. Herceptin mechanism of action is binding itself to HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals and thus decreasing the mutation of cells. Herceptin acts as an immune targeted therapy for breast cancer patients.

Market Dynamics

Product approvals and launches are the factors driving the growth of the global herceptin biosimilar market. For instance, in February 2020, Pfizer Inc., a biotechnology and pharmaceutical company in the U.S., launched the trastuzumab biosimilar, Trazimera, for treatment of human epidermal growth receptor causing breast cancer and metastatic gastric cancer.

Key features of the study:

  • This report provides in-depth analysis of the global herceptin biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Herceptin biosimilar market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global herceptin biosimilar market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herceptin biosimilar market.

Detailed Segmentation:

  • Global Herceptin Biosimilar Market, By Indication:
    • Breast Cancer
    • Gastric Cancer
    • Others
  • Global Herceptin Biosimilar Market, By Distribution Channel :
    • Hospitals
    • Oncology Centers
    • Others
  • Global Herceptin Biosimilar Market, By Region:
    • North America
      • By Indication:
      • Breast Cancer
      • Gastric Cancer
      • Others
      • By Distribution Channel :
      • Hospital
      • Oncology Centers
      • Others
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Indication:
      • Breast Cancer
      • Gastric Cancer
      • Others
      • By Distribution Channel :
      • Hospital
      • Oncology Centers
      • Others
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Indication:
      • Breast Cancer
      • Gastric Cancer
      • Others
      • By Distribution Channel :
      • Hospital
      • Oncology Centers
      • Others
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Indication:
      • Breast Cancer
      • Gastric Cancer
      • Others
      • By Distribution Channel :
      • Hospital
      • Oncology Centers
      • Others
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Indication:
      • Breast Cancer
      • Gastric Cancer
      • Others
      • By Distribution Channel :
      • Hospital
      • Oncology Centers
      • Others
      • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Indication:
      • Breast Cancer
      • Gastric Cancer
      • Others
      • By Distribution Channel :
      • Hospital
      • Oncology Centers
      • Others
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Amgen Inc. *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • AryoGen Biopharma
    • Biocon Limited
    • Celltrion Inc.
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Accord Healthcare Ltd.
    • Gedeon Richter Plc.
    • Genor Biopharma Company Ltd
    • Mabion SA
    • Mylan N.V.
    • Roche Holding AG
    • Samsungbioepis Co,.Ltd

o

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI4258

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel

Market Snippet, By Region

  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Impact Analysis
  • Market Opportunities
  • Regulatory Scenario
  • Recent Product Approval/ Launch
  • Key Development
  • PEST Analysis
  • Epidemiology
  • Mergers and Acquisitions
  • Value Chain Analysis

4. Global Herceptin Biosimilar Market, Impact of COVID-19 Pandemic

  • Post COVID-19 Impact
  • Demand and Supply Chain Analysis
  • Government Initiative

5. Global Herceptin Biosimilar Market, By Indication, 2017 - 2028 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
    • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Gastric Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Herceptin Biosimilar Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
    • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Oncology Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Herceptin Biosimilar Market, By Region, 2017 - 2028 (US$ Mn)

  • Introduction
  • Market Share Analysis, By Region, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, For Countries, 2017 - 2028
  • North America
  • Introduction
  • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Company Profiles
  • Amgen Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • AryoGen Biopharma
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Biocon Limited
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Celltrion Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Pfizer Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Merck & Co., Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Accord Healthcare Ltd.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Gedeon Richter Plc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Genor Biopharma Company Ltd
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Mabion SA
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Mylan N.V.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Market Strategies
  • Roche Holding AG
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Market Strategies
  • Samsungbioepis Co,.Ltd
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Market Strategies

Browse 33 market data tables and 32 figures on "Herceptin Biosimilar Market- Global forecast to 2028".